89Bio nabs $60 mln Series A
San Francisco and Israel-based 89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders, has raised $60 million in Series A financing. OrbiMed Israel, OrbiMed US and Longitude Capital led the round with participation from RA Capital Management and Pontifax.
25 October 2018•1 min read
